Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis

BACKGROUND: We assessed the cost-effectiveness of adding a quadrivalent (6/11/16/18) human papillomavirus (HPV) vaccine to the current screening programme in the UK compared to screening alone. METHODS: A Markov model of the natural history of HPV infection incorporating screening and vaccination wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulasingam, Shalini L, Benard, Steve, Barnabas, Ruanne V, Largeron, Nathalie, Myers, Evan R
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2290741/
https://www.ncbi.nlm.nih.gov/pubmed/18279515
http://dx.doi.org/10.1186/1478-7547-6-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2290741/
https://www.ncbi.nlm.nih.gov/pubmed/18279515
http://dx.doi.org/10.1186/1478-7547-6-4

Ejemplares similares